EUVIMEDEUVIMED entdecken
Crossref

Impact of Single-Time-Point Estimates of 177 Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles

Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J Gross, Simona Grozinsky-Glasberg, Simona Ben-Haim

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.122.264923 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Alexandre Chicheportiche und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Biophysics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Isra…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dosimetry after 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) enables estimation of radiation doses absorbed by normal organs and target lesions. This process is time-consuming and requires multiple posttreatment studies on several subsequent days. In a previous study, we described a newly developed multiple-linear-regression model to predict absorbed doses (ADs) from a single-time-point (STP) posttreatment study acquired 168 h after the first infusion and 24 h after the following ones, with similar results to the standard multiple-time-point (MTP) protocol. The present study aimed to validate this model in a large patient cohort and to assess whether STP dosimetry affects patient management decisions compared with our MTP protocol.

Methods

Quantitative 177Lu-DOTATATE SPECT/CT post-PRRT data from 159 consecutive patients (172 therapies, 477 therapy cycles) were retrospectively analyzed. ADs obtained from an STP model were compared with those obtained using an MTP model. We evaluated the impact of the STP model on the decision on whether PRRT should be stopped because of an expected kidney AD exceeding the safety threshold. We hypothesized that patient management based on the STP model does not differ from that based on the MTP model in at least 90% of the cases.

Results

There was no difference in management decisions between the MTP and STP models in 170 of 172 therapies (98.8%). A Fisher χ2 test for combined probabilities produced a composite P value of 0.0003. Mean cumulative AD relative differences between the STP and MTP models were 0.8% ± 8.0%, -7.7% ± 4.8%, 0.0% ± 11.4%, -2.8% ± 6.3%, and -2.1% ± 18.4% for kidneys, bone marrow, liver, spleen, and tumors, respectively (Pearson r = 0.99 for all), for patients who underwent 4 therapy cycles. Similar results were obtained with fewer therapy cycles.

Conclusion

Estimated radiation ADs and patient management decisions were similar with the STP and MTP models. The STP model can simplify the dosimetry process while also reducing scanner and staff time and improving patient comfort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOrganometallic CompoundsHumansRetrospective StudiesOctreotideRadiometryKidneySingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

177Lu-DOTATATEPRRTSPECT/CTinternal dosimetrypeptide receptor radionuclide therapysingle time point

Substanzen

OctreotideOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Biophysics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; alexandre@hadassah.org.il.
  • Department of Nuclear Medicine and Biophysics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Neuroendocrine Tumor Unit, ENETS Center of Excellence, Hebrew University of Jerusalem, Jerusalem, Israel; and.
  • University College London, London, United Kingdom.

Zitieren

APA

Chicheportiche, A., Sason, M., Zidan, M., Godefroy, J., Krausz, Y., Gross, D. J., Grozinsky-Glasberg, S., & Ben-Haim, S. (2023). Impact of Single-Time-Point Estimates of 177 Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.122.264923

Vancouver

Chicheportiche A, Sason M, Zidan M, Godefroy J, Krausz Y, Gross DJ, et al. Impact of Single-Time-Point Estimates of 177 Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.122.264923

BibTeX
@article{Chicheportiche2023,
  author = {Chicheportiche, Alexandre and Sason, Moshe and Zidan, Mahmoud and Godefroy, Jeremy and Krausz, Yodphat and Gross, David J and Grozinsky-Glasberg, Simona and Ben-Haim, Simona},
  title = {Impact of Single-Time-Point Estimates of 177 Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.122.264923}
}
Kostenlos starten →